Skip to main content Skip to search Skip to main navigation

EU: Environment Committee Comments on EU Regulation Regarding Critical Medicines

The Environment Committee of the European Parliament has issued its opinion on the proposed EU Regulation to strengthen the availability of critical medicines. Key recommendations include fast-track permitting, simplified environmental assessments, and support for strategic manufacturing projects to boost EU production capacity.

The Committee calls for better coordination among Member States and a balanced, data-driven approach to avoid disruptions caused by overlapping environmental and chemical legislation. High environmental standards should be upheld without compromising medicine availability.

Transparency is emphasised: all environmental and authorisation data should be accessible via a central online portal. Procedures must remain efficient and time-bound, avoiding unnecessary burdens. Rapid activation of strategic projects is supported, especially to address urgent shortages.


Source:

EU Parliament: Opinion of the Committee on the Environment, Climate and Food Safety

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: New Guideline on Elemental Impurities in Veterinary Medicinal Products

EMA: New Guideline on Elemental Impurities in Veterinary Medicinal Products

The EMA has published the new Guideline on risk management requirements for elemental impurities in veterinary medicinal products (EMA/CVMP/426245/2023). It was developed to consolidate the existing documents on risk assessment and the management of elemental impurities in veterinary medicinal products into a single, clearly structured guideline.
Read more
Organic Impurities in Active Pharmaceutical Ingredients – Nitrosamines

Organic Impurities in Active Pharmaceutical Ingredients – Nitrosamines

Since the unexpected discovery of N-nitrosamines in sartans in 2018, what began as isolated recalls has evolved into a permanent, lifecycle-wide compliance challenge for the pharmaceutical industry. With tightening EMA and FDA expectations, substance-specific limits, and intensified GMP scrutiny, companies must now proactively control nitrosamine risks.

Read more
What are the Different Priorities of the Quality Assurance and IT Departments when Operating Computerised Systems?

What are the Different Priorities of the Quality Assurance and IT Departments when Operating Computerised Systems?

Here's the answer:
Read more
EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA and PIC/S have published a concept paper announcing a targeted revision of Annex 6 Manufacture of Medicinal Gases of the EU GMP Guide. The last update dates from 2010. The revision aims to reflect current manufacturing practice, technological progress and lessons learned from the COVID-19 pandemic.

Read more
EMA: Concept Paper on the Revision of Annex 15

EMA: Concept Paper on the Revision of Annex 15

EMA and PIC/S have published a concept paper outlining a targeted revision of Annex 15 (Qualification and Validation).

Read more
What do Typical Manufacturing Processes for Sterile Products look like?

What do Typical Manufacturing Processes for Sterile Products look like?

Here's the answer:
Read more
Previous
Next